-+ 0.00%
-+ 0.00%
-+ 0.00%

Palisade Bio Two Abstracts Selected For Poster Presentation At Two Premier International Inflammatory Bowel Diseases Meetings

Benzinga·01/16/2026 13:33:18
Listen to the news

Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026.